Literature DB >> 24100046

Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy.

Dan Liu1, Kai Hu, Markus Niemann, Sebastian Herrmann, Maja Cikes, Stefan Störk, Philipp Daniel Gaudron, Stefan Knop, Georg Ertl, Bart Bijnens, Frank Weidemann.   

Abstract

BACKGROUND: Differentiation of cardiac amyloidosis (CA) from other causes of concentric left ventricular hypertrophy remains a clinical challenge, especially in patients with preserved ejection fraction at the early disease stages. METHODS AND
RESULTS: Consecutive hypertrophic patients with CA, isolated arterial hypertension, Fabry disease, and Friedreich ataxia (n=25 per group) were investigated; 25 healthy volunteers served as a control group. Standard echocardiography was performed, and segmental longitudinal peak systolic strain (LSsys) in the septum was assessed by 2-dimensional speckle tracking imaging. Indices of left ventricular hypertrophy and ejection fraction were similar among all patient groups. Deceleration time of early filling was significantly lower in patients with CA (147±46 milliseconds) compared with those with isolated arterial hypertension, Fabry disease, or control subjects (all P<0.0125). Septal basal LSsys (-6±2%) was significantly lower in patients with CA compared with those with isolated arterial hypertension (-14±6%), Fabry disease (-12±5%), Friedreich ataxia (-16±2%), or control subjects (-17±3%; all P<0.001), whereas septal apical LSsys was similar among all patient groups and control subjects (all P>0.05). A data-driven cutoff value for the ratio of septal apical to basal LSsys ratio >2.1 differentiated CA from other causes of left ventricular hypertrophy (sensitivity, 88%; specificity, 85%; positive predictive value, 67%; negative predictive value, 96%). The prevalence of septal apical to basal LSsys ratio >2.1 plus deceleration time of early filling <200 milliseconds was 88% in CA but 0% in all other groups.
CONCLUSIONS: A systolic septal longitudinal base-to-apex strain gradient (septal apical to basal LSsys ratio >2.1), combined with a shortened diastolic deceleration time of early filling (deceleration time of early filling <200 milliseconds), aids in differentiating CA from other causes of concentric left ventricular hypertrophy.

Entities:  

Keywords:  amyloidosis; differential diagnosis; echocardiography; hypertrophy, left ventricular

Mesh:

Year:  2013        PMID: 24100046     DOI: 10.1161/CIRCIMAGING.113.000683

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  49 in total

Review 1.  Novel Approaches for the Management of AL Amyloidosis.

Authors:  Nisha S Joseph; Jonathan L Kaufman
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 2.  Advances in Treatment of Cardiac Amyloid.

Authors:  Cherie N Dahm; R Frank Cornell; Daniel J Lenihan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

3.  Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis.

Authors:  Kai Hu; Dan Liu; Peter Nordbeck; Maja Cikes; Stefan Störk; Bastian Kramer; Philipp Daniel Gaudron; Andreas Schneider; Stefan Knop; Georg Ertl; Bart Bijnens; Frank Weidemann; Sebastian Herrmann
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-16       Impact factor: 2.357

Review 4.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

5.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

6.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

7.  Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management.

Authors:  Vasvi Singh; Alexander Tiemeier; Saurabh Malhotra
Journal:  J Nucl Cardiol       Date:  2019-02-20       Impact factor: 5.952

Review 8.  Echocardiographic assessment of left ventricular systolic function.

Authors:  Lars Gunnar Klaeboe; Thor Edvardsen
Journal:  J Echocardiogr       Date:  2018-11-02

9.  How to image cardiac amyloidosis.

Authors:  Rodney H Falk; Candida C Quarta; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2014-05       Impact factor: 7.792

Review 10.  Cardiac Amyloidosis: Diagnosis and Treatment Strategies.

Authors:  Mirela Tuzovic; Eric H Yang; Arnold S Baas; Eugene C Depasquale; Mario C Deng; Daniel Cruz; Gabriel Vorobiof
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.